• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

Fauci says he experienced ‘Paxlovid rebound’ but says the drug stopped his infection from becoming more severe

By
Erin Prater
Erin Prater
Down Arrow Button Icon
By
Erin Prater
Erin Prater
Down Arrow Button Icon
June 29, 2022, 4:09 PM ET
Updated June 29, 2022, 10:10 PM ET
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, attends a COVID federal response hearing on Capitol Hill on June 16.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, attends a COVID federal response hearing on Capitol Hill on June 16. Joe Raedle—Getty Images

Chief presidential medical adviser Dr. Anthony Fauci said this week that he experienced a so-called Paxlovid rebound after he took the antiviral to aid his recovery from COVID, but later clarified that the drug was important to his recovery. 

The symptoms he developed after he took the pill were more severe than those he had initially, he said.

“After I finished the five days of Paxlovid, I reverted to negative on an antigen test for three days in a row,” Fauci, 81, said during an event at Foreign Policy’s Global Health Forum, Bloomberg reported. “And then on the fourth day, just to be absolutely certain, I tested myself again.”

“I reverted back to positive,” he said. 

He then began a second course of Paxlovid when symptoms emerged “much worse than the first go-around,” he said. Fauci said he was feeling “reasonably good” as of Tuesday.

However, Fauci later told the New York Times that Paxlovid kept him away from the hospital, and stopped his infection from becoming more severe initially. “Paxlovid did what it was supposed to do,” he said in an interview with the outlet.

Paxlovid is a pill approved for treatment of COVID-19 in high-risk adults. It has emergency-use authorization from the U.S. Food and Drug Administration.

Fauci was prescribed Paxlovid owing to his advanced age, which puts him at greater risk for a severe outcome from COVID. He is fully vaccinated and twice boosted, Bloomberg reported.

Earlier this month Pfizer, which manufactures the medication, announced that it would stop adding new participants to a trial of the drug among COVID patients at low risk of hospitalization and death. The study failed to demonstrate that the drug reduced symptoms, or hospitalizations and deaths in a statistically significant way, according to Bloomberg.

The U.S. Centers for Disease Control and Prevention in May issued a health advisory regarding “COVID-19 rebound,” also known as “Paxlovid rebound.” 

But “a brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status,” the advisory stated.

There is no evidence that additional treatment is needed for rebound cases, the CDC said in the advisory. It is unclear why Fauci took a second course of Paxlovid, in light of this guidance.
Patients who rebound after taking Paxlovid will need to isolate again for five days, according to the CDC. Such patients can report their rebound cases here.

June 29, 2022: This story has been updated to reflect additional comments that Dr. Anthony Fauci made about his Paxlovid treatment

Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Author
By Erin Prater
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Nutricost Probiotic Complex Review (2026): Expert Approved
HealthDietary Supplements
Nutricost Probiotic Complex Review (2026): Expert Approved
By Christina SnyderMarch 31, 2026
6 hours ago
The 6 Best Weight Loss Supplements for Women of 2026: Nutritionist Approved
HealthDietary Supplements
The 6 Best Weight Loss Supplements for Women of 2026: Nutritionist Approved
By Christina SnyderMarch 30, 2026
1 day ago
Toryo Ito, the vice abbot of the oldest Zen temple in Kyoto
SuccessCareers
Buddhist monk says workers struggle to wind down from fast-paced office culture—he shares a 30-second tip to reset your nervous system
By Emma BurleighMarch 29, 2026
3 days ago
Are you addicted to technology? 6 questions experts use to help spot red flags
Big TechHealth
Are you addicted to technology? 6 questions experts use to help spot red flags
By Kristin StollerMarch 28, 2026
4 days ago
The Best Omega-3 Supplements (2026): An Expert Guide
HealthDietary Supplements
The Best Omega-3 Supplements (2026): An Expert Guide
By Emily PharesMarch 27, 2026
4 days ago
The 5 Best Online Dietitians of 2026: Help to Reach Your Nutrition Goals
HealthDietary Supplements
The 5 Best Online Dietitians of 2026: Help to Reach Your Nutrition Goals
By Christina SnyderMarch 27, 2026
4 days ago

Most Popular

Jerome Powell says the $39 trillion national debt is ‘not unsustainable,’ but warns the trajectory ‘will not end well’
Economy
Jerome Powell says the $39 trillion national debt is ‘not unsustainable,’ but warns the trajectory ‘will not end well’
By Fortune EditorsMarch 30, 2026
1 day ago
A man used AI to call 3,000 Irish bartenders to track the cost of Guinness. Now pubs are lowering their prices to compete
AI
A man used AI to call 3,000 Irish bartenders to track the cost of Guinness. Now pubs are lowering their prices to compete
By Fortune EditorsMarch 30, 2026
1 day ago
A CEO trying to reindustrialize America says blue-collar pay is headed for 'massive hyperinflation' and kids should skip college to become welders
Success
A CEO trying to reindustrialize America says blue-collar pay is headed for 'massive hyperinflation' and kids should skip college to become welders
By Fortune EditorsMarch 30, 2026
1 day ago
Current price of gold as of March 30, 2026
Personal Finance
Current price of gold as of March 30, 2026
By Fortune EditorsMarch 30, 2026
1 day ago
The federal government shed 385,000 employees last year. Now the Trump administration is on a blitz to hire Gen Z workers
Politics
The federal government shed 385,000 employees last year. Now the Trump administration is on a blitz to hire Gen Z workers
By Fortune EditorsMarch 31, 2026
18 hours ago
Markets cheer as Trump threatens to abandon Iran war, but Jamie Dimon sides with allies: ‘Win this thing and clean up the straits’
Energy
Markets cheer as Trump threatens to abandon Iran war, but Jamie Dimon sides with allies: ‘Win this thing and clean up the straits’
By Fortune EditorsMarch 31, 2026
9 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.